Company commences Technegas trial in U.S.

11/20/2012 | ProactiveInvestors.co.au (Australia)

Cyclopharm has enrolled the first patient in a U.S. clinical trial involving its Technegas product, a gas inhaled by patients before imaging to improve detection of blood clots in the lungs. The multi-center study will eventually involve 750 patients and is expected to be completed in 18 months.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO